UK biotech raises ￡3.5 billion in 2024
This issue of our newsletter is supported by Altasciences.
The past year has been one of ups and downs for the biotech and healthcare sectors in the U.K. But according to a report by the UK BioIndustry Association (BIA), which revealed how investments played a part in research and development (R&D) in the country, equity financing was at quite a high last year – around ￡3.5 billion ($4.36 million) was raised by the industry, an astonishing 94% increase from 2023.
The venture capital landscape also soared by 64.8% since 2023. The sector raised ￡2.06 billion (￡2.56 billion) and, this time around, attracted investors from North America, who were keen on later-stage deals. However, not a single U.K. biotech went public last year, with the initial public offering (IPO) market having been stagnant for two years in a row now.?
To find out more, read the full article: “U.K. biotech defies the odds, raising ￡3.5B in 2024”
A MESSAGE FROM OUR SPONSOR ALTASCIENCES
Discover the dynamic landscape of GLP-1 drug development
This issue of The Altascientist explores the current and future of GLP-1 receptor agonists, including their expanding applications in treating various health conditions. Packed with case studies, this edition covers all aspects of early-phase development: preclinical models, bioanalytical assays, clinical study designs, and the manufacturing of GLP-1s.
?? Download now
Want to advertise with us? Become our next sponsor.
?? More noteworthy articles from this week:
Pancreatic cancer is considered one of the most aggressive and deadliest cancers around, largely because it is often diagnosed at an advanced stage. It has been increasing in incidence for decades and is now the third leading cause of cancer death in the U.S., with projections indicating that it will be second only to lung cancer in its lethality by 2025. But why exactly is pancreatic cancer so difficult to treat and what drugs are currently in the therapeutic pipeline?
领英推荐
Genomics, which deals with the mapping of genomes, is a booming industry that aims to advance precision medicine to address a host of diseases. You may have heard of the big names in the business, like Illumina, Oxford Nanopore Technologies, and Thermo Fisher Scientific. But there are a number of genomics startups that have sprouted up in the past decade or so to strengthen their sequencing technologies to aid in disease prevention and treatment.?
The companies Immunovant, Verdiva Bio, and Akero Therapeutics bagged the biggest biotech funding rounds overall in January 2025 across private and public funding types. In this article, we break down last month’s private and public fundraising activity, looking at the largest rounds in more detail.
Akribion Therapeutics, a German biotech company, announced an €8 million ($8.2 million) seed round. It is working on G-dase E, a programmable nuclease designed to selectively deplete specific cell populations based on intracellular RNA markers. Unlike traditional CRISPR technology, which edits genes, Akribion’s approach aims to destroy cells outright. Could RNA-guided cell depletion be the next frontier of oncology? And how does Akribion Therapeutics’ approach compare to existing technologies?
Cancer has long been one of the most persistent and deadly diseases, and with its ability to evolve, resist treatment, and spread relentlessly, it has left scientists grappling for solutions. Yet, amid the uncertainty, the landscape of cancer treatments is shifting. Once limited to chemotherapy and radiation, treatment options have expanded since and continue to do so. As we observe World Cancer Day today, let us look at some of the trends in oncology expected to improve cancer care in 2025.?
Solid tumors present a big challenge for current treatments. However, a new approach might provide the answers - Tumor Activated Therapy. By targeting specific proteins common in all solid tumor micro-environments, Seekyo scientists think this can induce self-destruction of the tumor itself. Seekyo’s lead therapy, SKY01, can only be activated within the tumor, making it a highly-targeted solution. This week, our guest is Seekyo Therapeutics’ CEO, Oury Chetboun.?
Identifying novel targets and suitable drugs for solid tumors could lead to true breakthroughs, increasing efficacy and reducing side effects. Cancer tissue biobanks combined with a detailed knowledge of the differences between tumor and healthy tissue and a deep understanding of tumor heterogeneity are cornerstones for developing new treatments.
??Enjoying these articles??Never miss a single publication of Labiotech by becoming a part of our community! Click here to join our mailing list.